DO-BO

Do Swiss Reimbursement Reforms Open Doors—or Raise New Barriers, Petra Erni?

Tune in to this episode of MAP – The Market Access Podcast, to hear from Dr. Stefan Walzer as he speaks with Swiss reimbursement expert Petra Erni, who brings a rare perspective from both the industry and payer sides.

Together they explore the evolving Swiss drug reimbursement landscape, discussing the rise of cost consequence models, the growing role of health economic evidence, early access pathways, and strategic pricing challenges in Switzerland. Essential listening for pharma, market access, and health policy professionals—especially those eyeing the Swiss market.

Related

Is the EU Joint Clinical Assessment just another administrative layer, or the start of a truly European HTA? In this MAP episode, Dr. Stefan Walzer talks with Dr. Oriol Solà-Morales, physician, health economist, founder and CEO of HITT and founding member of EUnetHTA, about what the first JCA reports reveal. Drawing on Spain’s shift from […]

AI is reshaping health economics and outcomes research (HEOR) – but where does it truly belong? In this MAP episode, Dr. Stefan Walzer talks with Haidong Feng, Associate Principal Scientist at Merck, about “human in the loop” versus “AI in the loop” and why the two complement rather than contradict each other. Haidong explains why […]

When the US benchmarks drug prices against other countries, the whole world feels it. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Brittany La Couture of Applied Policy, a health policy attorney with eight years at the Centers for Medicare & Medicaid Services, to unpack the US […]